New analysis shows use of EXPAREL associated with improved clinical and economic outcomes
Pacira BioSciences announced new data on the use of EXPAREL® (bupivacaine liposome injectable suspension) following total hip arthroplasty. The findings show that patients receiving EXPAREL had a significant reduction in opioid use, hospital length of stay (LOS), and total hospitalization costs. June 12, 2019